» Articles » PMID: 29898390

Psychedelics Promote Structural and Functional Neural Plasticity

Abstract

Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These changes in neuronal structure are accompanied by increased synapse number and function, as measured by fluorescence microscopy and electrophysiology. The structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways and could possibly explain the clinical effectiveness of these compounds. Our results underscore the therapeutic potential of psychedelics and, importantly, identify several lead scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds as safe, effective, and fast-acting treatments for depression and related disorders.

Citing Articles

Licit use of illicit drugs for treating depression: the pill and the process.

Torrado Pacheco A, Moghaddam B J Clin Invest. 2025; 134(12).

PMID: 40047885 PMC: 11178541. DOI: 10.1172/JCI180217.


Lysergic Acid Diethylamide Alters the Effects of Brain Stimulation in Rodents.

Dwiel L, Henricks A, Bragg E, Nicol J, Gui J, Doucette W Psychedelic Med (New Rochelle). 2025; 1(1):43-53.

PMID: 40047011 PMC: 11658655. DOI: 10.1089/psymed.2022.0014.


A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to....

Hibicke M, Kramer H, Nichols C Psychedelic Med (New Rochelle). 2025; 1(1):54-67.

PMID: 40047006 PMC: 11661400. DOI: 10.1089/psymed.2022.0012.


Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.

Nicholas C, Horton D, Malicki J, Baltes A, Hutson P, Brown R Psychedelic Med (New Rochelle). 2025; 1(4):253-261.

PMID: 40046866 PMC: 11661506. DOI: 10.1089/psymed.2023.0012.


A Heuristic Approach: Against Consensus Definitions of Psychedelics.

Lepow L, Kronman H, Yehuda R Psychedelic Med (New Rochelle). 2025; 1(4):190-194.

PMID: 40046859 PMC: 11658663. DOI: 10.1089/psymed.2023.0031.


References
1.
Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

2.
Castello N, Nguyen M, Tran J, Cheng D, Green K, LaFerla F . 7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One. 2014; 9(3):e91453. PMC: 3948846. DOI: 10.1371/journal.pone.0091453. View

3.
Murrough J, Perez A, Pillemer S, Stern J, Parides M, Aan Het Rot M . Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2012; 74(4):250-6. PMC: 3725185. DOI: 10.1016/j.biopsych.2012.06.022. View

4.
Alper K . Ibogaine: a review. Alkaloids Chem Biol. 2001; 56:1-38. DOI: 10.1016/s0099-9598(01)56005-8. View

5.
Russo S, Mazei-Robison M, Ables J, Nestler E . Neurotrophic factors and structural plasticity in addiction. Neuropharmacology. 2008; 56 Suppl 1:73-82. PMC: 2635335. DOI: 10.1016/j.neuropharm.2008.06.059. View